-
公开(公告)号：US20200237890A1
公开(公告)日：2020-07-30
申请号：US16844060
申请日：2020-04-09
Applicant: Pfizer Inc.
Inventor： David Cooper , Kathrin Ute Jansen , Michael William Pride
IPC: A61K39/09 , A61K39/385
Abstract: An object of the present invention is to provide immunogenic compositions for protection against S. pneumoniae, in particular against S. pneumoniae serogroup 9, while limiting the number of conjugates. The present invention therefore relates to new immunogenic compositions for use in pneumococcal vaccines and to vaccination of human subjects, in particular infants and elderly, against pneumococcal infections using said immunogenic compositions.
-
2.发明申请公开(公告)号：US20240374699A1
公开(公告)日：2024-11-14
申请号：US18531055
申请日：2023-12-06
Applicant: Pfizer Inc.
Inventor： Emilio Anthony Emini , Wendy Jo Watson , Avvari Krishna Prasad , Mingming Han , Jin-Hwan Kim , Jianxin Gu , Yu-ying Yang , Rajesh Kumar Kainthan , David Cooper , Michael William Pride , Kathrin Ute Jansen
Abstract: The present invention relates to new immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates) and uses thereof. Immunogenic compositions of the present invention will typically comprise at least one glycoconjugate from a S. pneumoniae serotype not found in PREVNAR®, SYNFLORIX® and/or PREVNAR 13®. The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumococcal infections using said novel immunogenic compositions.
-
3.发明授权公开(公告)号：US11090375B2
公开(公告)日：2021-08-17
申请号：US16899738
申请日：2020-06-12
Applicant: Pfizer Inc.
Inventor： Emilio Anthony Emini , Wendy Jo Watson , Avvari Krishna Prasad , Mingming Han , Jin-Hwan Kim , Jianxin Gu , Yu-ying Yang , Rajesh Kumar Kainthan , David Cooper , Michael William Pride , Kathrin Ute Jansen
Abstract: The present invention relates to new immunogenic compositions comprising conjughated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates) and uses thereof. Immunogenic compositions of the present invention will typically comprise at least one glycoconjugate from a S. pneumoniae serotype not found in PREVNAR®, SYNFLORIX® and/or PREVNAR 13®. The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumococcal infections using said novel immunogenic compositions.
-
公开(公告)号：US20180000922A1
公开(公告)日：2018-01-04
申请号：US15542802
申请日：2016-01-05
Applicant: Pfizer Inc.
Inventor： David Cooper , Kathrin Ute Jansen , Michael William Pride
IPC: A61K39/09 , A61K39/385 , A61K39/00
CPC classification number: A61K39/092 , A61K39/385 , A61K2039/55544 , A61K2039/58 , A61K2039/70
Abstract: An object of the present invention is to provide immunogenic compositions for protection against S. pneumoniae, in particular against S. pneumoniae serogroup 9, while limiting the number of conjugates. The present invention thereforerelates to new immunogenic compositions for use in pneumococcal vaccines and to vaccination of human subjects, in particular infants and elderly, against pneumoccocal infections using said immunogenic compositions.
-
5.发明公开公开(公告)号：US20240189410A1
公开(公告)日：2024-06-13
申请号：US18535116
申请日：2023-12-11
Applicant: Pfizer Inc.
Inventor： Annaliesa Sybil Anderson , Marina A. Gonzalez-Garis , Lei Hu , Isis Kanevsky , Paul Arthur Liberator , Justin Keith Moran , Lynn Marie Phelan , Michael William Pride , Shuai Shi , Naveen Surendran
CPC classification number: A61K39/08 , A61K39/39 , A61P31/04 , A61K2039/55561
Abstract: The present invention relates to immunogenic compositions that comprise a Clostridioides difficile toxoid A and/or a C. difficile toxoid B, and an adjuvant, and methods of use thereof. The present invention further relate to a methods for eliciting an enhanced immune response in a human against a C. difficile infection. The methods include administering to the human an effective dose of an immunogenic composition, which includes a C. difficile toxoid and an adjuvant, wherein the composition is administered two times.
-
Patent Agency Ranking
公开(公告)号：US20240000912A1
公开(公告)日：2024-01-04
申请号：US18034239
申请日：2021-11-01
Applicant: Pfizer Inc.
Inventor： Annaliesa Sybil Anderson , Seema Shridhar Gangolli , Kathrin Ute Jansen , Avvari Krishna Prasad , Michael William Pride , Ingrid Lea Scully , Wendy Jo Watson
CPC classification number: A61K39/092 , A61P31/04 , A61K2039/70
Abstract: An object of the present invention is to provide immunogenic compositions for protection against S. pneumoniae, in particular against S. pneumoniae serogroup 15, while limiting the number of conjugates. The present invention therefore relates to new immunogenic compositions for use in pneumococcal vaccines and to vaccination of human subjects, in particular infants and elderly, against pneumococcal infections using said immunogenic compositions.
-
公开(公告)号：US20210393764A1
公开(公告)日：2021-12-23
申请号：US17463691
申请日：2021-09-01
Applicant: Pfizer Inc.
Inventor： David Cooper , Kathrin Ute Jansen , Michael William Pride
IPC: A61K39/09 , A61K39/385
Abstract: An object of the present invention is to provide immunogenic compositions for protection against S. pneumoniae, in particular against S. pneumoniae serogroup 9, while limiting the number of conjugates. The present invention therefore relates to new immunogenic compositions for use in pneumococcal vaccines and to vaccination of human subjects, in particular infants and elderly, against pneumoccocal infections using said immunogenic compositions.
-
8.发明授权公开(公告)号：US11160855B2
公开(公告)日：2021-11-02
申请号：US15286696
申请日：2016-10-06
Applicant: Pfizer Inc.
Inventor： Emilio Anthony Emini , Wendy Jo Watson , Avvari Krishna Prasad , Mingming Han , Jin-Hwan Kim , Jianxin Gu , Yu-ying Yang , Rajesh Kumar Kainthan , David Cooper , Michael William Pride , Kathrin Ute Jansen
Abstract: The present invention relates to new immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates) and uses thereof. Immunogenic compositions of the present invention will typically comprise at least one glycoconjugate from a S. pneumoniae serotype not found in PREVNAR®, SYNFLORIX® and/or PREVNAR 13®. The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumoccocal infections using said novel immunogenic compositions.
-
9.发明申请Immunogenic Compositions Comprising Conjugated Capsular Saccharide Antigens and Uses Thereof 有权包含共轭荚膜糖抗原的免疫原性组合物及其用途公开(公告)号：US20150202309A1
公开(公告)日：2015-07-23
申请号：US14597488
申请日：2015-01-15
Applicant: PFIZER INC.
Inventor： Emilio Anthony Emini , Wendy Jo Watson , Avvari Krishna Prasad , Mingming Han , Jin-Hwan Kim , Jianxin Gu , Yu-ying Yang , Rajesh Kumar Kainthan , David Cooper , Michael William Pride , Kathrin Ute Jansen
CPC classification number: A61K47/4833 , A61K39/092 , A61K47/646 , A61K2039/6037 , A61K2039/70 , Y02A50/466
Abstract: The present invention relates to new immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates) and uses thereof. Immunogenic compositions of the present invention will typically comprise at least one glycoconjugate from a S. pneumoniae serotype not found in PREVNAR®, SYNFLORIX® and/or PREVNAR 13®. The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumoccocal infections using said novel immunogenic compositions.
Abstract translation: 本发明涉及包含结合性肺炎链球菌荚膜糖抗原（糖缀合物）的新的免疫原性组合物及其应用。 本发明的免疫原性组合物通常将包含至少一种来自PREVNAR，SYNFLORIX和/或PREVNAR 13中没有发现的肺炎链球菌血清型的糖缀合物。 本发明还涉及使用所述新型免疫原性组合物对人受试者，特别是婴儿和老年人免疫肺炎球菌感染。
-
公开(公告)号：US20240238400A1
公开(公告)日：2024-07-18
申请号：US18430068
申请日：2024-02-01
Applicant: Pfizer Inc.
Inventor： Fiona Laichu Lin , Viliam Pavliak , Michael William Pride , Shite Sebastian
CPC classification number: A61K39/092 , A61K2039/58 , A61K2039/6037 , A61K2039/70
Abstract: An object of the present invention is to provide immunogenic compositions for protection against S. pneumoniae, in particular against S. pneumoniae serogroup 10A and 39, while limiting the number of conjugates. The present invention therefore relates to new immunogenic compositions for use in pneumococcal vaccines and to vaccination of human subjects, in particular infants and elderly, against pneumoccocal infections using said immunogenic compositions.
-
-
-
-
-
-
-
-
-
Search Results
22
records
(took 0.02 seconds)
